Compare stocks

MedinCell S.A. is a pharmaceutical company focused on the development of long-acting injectable therapeutics. Operating in the healthcare industry, MedinCell specializes in drug delivery technology that combines global health needs with the potential for improved patient adherence. The company is known for its proprietary BEPO technology, which allows for controlled and sustained release of medication. Founded in 2002 and headquartered in Jacou, France, the company works on a pipeline of therapeutic solutions across various segments, including pain management, contraception, and mental health. MedinCell's strategic position is reinforced by its collaborative partnerships and its innovative approach to addressing unmet medical needs with affordable healthcare solutions.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.